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Abstract: Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneu-
mococcal disease (IPD) worldwide. However, the influence of regional vaccine uptake differences
on the changing epidemiology of IPD remains unclear. We aimed to examine the overall impact of
both seven- and 13-valent PCVs (PCV7 and PCV13) on IPD in Switzerland. Three-year periods from
2005–2010 and 2011–2019 were considered, respectively, as (early and late) PCV7 eras and (early,
mid and late) PCV13 eras. Vaccine coverage was estimated from a nationwide survey according
to east (German-speaking) and west (French/Italian-speaking) regions for each period. Reported
incidence rate ratios (IRRs) were compared between successive periods and regions using nationwide
IPD surveillance data. Overall IPD incidence across all ages was only 16% lower in the late PCV13
era compared to the early PCV7 era (IRR 0.83, 95% CI 0.79–0.88), due to increasing incidence of
non-PCV-type IPD (2.59, 2.37–2.83) in all age groups, except children <5 years. PCV uptake rates in
swiss children were slightly higher in the west than the east (p < 0.001), and were accompanied by
lower IPD incidences across all age groups in the former region. Post-PCV13, non-PCV serotypes 8,
22F and 9N were the major cause of IPD in adults ≥65 years. Increased PCV coverage in both areas
of Switzerland resulted in a decrease in vaccine-type and overall IPD incidence across all age groups,
in a regionally dependent manner. However, the rising incidence of non-vaccine-type IPD, exclusive
to older adults, may undermine indirect beneficial effects.
Keywords: Streptococcus pneumoniae; capsular polysaccharide; pneumococcal conjugate vaccines
(PCVs); Switzerland; serotype 3
1. Introduction
Invasive pneumococcal disease (IPD), comprising of pneumococcal pneumonia, bac-
teremia and meningitis, is a leading cause of mortality in children <5 years, adults≥65 years
and immunocompromised individuals. In 2005, the world health organization (WHO)
estimated 1.6 million annual IPD-related deaths, of which 0.7–1 million were in children
<5 years [1]. Since the introduction and widespread implementation of pneumococcal
conjugate vaccines (PCVs), especially in children <5 years, large reductions in the burden
and incidence of IPD have been observed in vaccinated children worldwide, as well as an
indirect herd protection effect among adults and unvaccinated individuals [2,3].
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In Switzerland, the heptavalent pneumococcal conjugate vaccine (PCV7, Prevenar®,
Pfizer), which covered serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, was first recommended
in 2001 for children <5 years with increased health risk for IPD, following a 3 + 1 dosing
schedule at 2, 4 and 6 months of age and a booster at 12–15 months [4]. In late 2005, PCV7
was additionally recommended as a supplementary (optional) vaccination for healthy
children <2 years, following a 2 + 1 dosing schedule at 2, 4 and 12 months with no catch-up
campaign [4]. Since late 2010, the thirteen-valent pneumococcal conjugate vaccine (PCV13,
Prevenar13®, Pfizer), which covers the PCV7 serotypes as well as six additional serotypes
(1, 3, 5, 6A, 7F, and 19A), has replaced PCV7 with a catch-up campaign extended up to
5 years of age [5]. In 2014, PCV13 became the only recommended pneumococcal vaccine,
replacing the 23-valent pneumococcal polysaccharide vaccine (PPV23, Pneumovax®23,
Merck) [5], which had been implemented since 2000 for individuals ≥5 years at higher
risk for IPD and adults ≥65 years, but had only shown a moderate protection efficacy
compared to PCV13 [6,7].
The impact of targeted pneumococcal vaccination programs on IPD has been investi-
gated in different countries [8–10]. However, little is known about the influence of regional
vaccine uptake differences on IPD epidemiology. We have previously shown higher (up to
five times) pneumococcal serotype-specific antibiotic resistance rates in western Switzer-
land (French-speaking) than the east (mostly German speaking) and attributed these to
a higher (up to 1.5 times) antibiotic consumption in the former [11,12]. Variations have
also been reported for methicillin-resistant staphylococcus aureus (MRSA) epidemiology
and human papillomavirus (HPV) vaccine uptake among the different language speak-
ing regions in Switzerland [13,14]. Switzerland therefore provides a unique setting for
studying regional variations in pneumococcal vaccine uptake and its association with
serotype epidemiology.
In this study, we investigate the impact of PCV introduction on IPD in Switzerland
and its regions during both PCV7 and PCV13 eras from 2005 to 2019 using nationwide IPD
and vaccination survey data. Our two objectives are (i) an overall analysis of IPD incidence
and serotype distribution in Switzerland during the PCV eras, and (ii) an assessment of
regional (east/west) variations in PCV coverage and its association with both age-specific
and overall IPD incidence.
2. Materials and Methods
2.1. Data Collection
In Switzerland, the Federal Office of Public Health (FOPH) has mandated all clinical
microbiology laboratories to send invasive Streptococcus pneumoniae isolates from sterile
body sites (blood; cerebrospinal fluid (CSF); pleural, joint and peritoneal fluid) to the Na-
tional Center for Invasive Pneumococci (NZPn). Isolates were received with corresponding
information on the patient’s age, gender and canton of origin. It is estimated that approxi-
mately 90% of all invasive isolates received at NZPn can be linked to physician-reported
IPD cases [15]. At the NZPn, isolates were cultured on Columbia sheep blood agar plates
and S. pneumoniae was confirmed using conventional methods (alpha hemolysis, optochin
susceptibility and bile solubility). The confirmed S. pneumoniae isolates were then assigned
serotypes based on the Quellung reaction.
The Swiss National Vaccination Coverage Survey (SNVCS) is a cross-sectional survey
which has been monitoring immunization coverage of children and adolescents (2-, 8- and
16- year-olds) across the 26 Swiss cantons every three years since 1999 [16]. Methodology
of data collection has been previously described [16]. In brief, information on children
and their parents were requested from the municipalities or central office of registry.
Children from each age group were randomly selected via simple random or cluster
sampling. Families of selected children were contacted up to three times by mail and once
by telephone, if permitted by the cantonal authorities, and asked to mail a copy of the
children’s vaccination card or upload it onto an online platform developed for the study.
Primary care physicians were contacted when vaccination data were unclear. Three cantons
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transmitted vaccination data for 8- and 16-year-olds collected by their school nurses. One
canton did not collect vaccination data for 8-year-olds. Vaccination information that was
not received through either of the aforementioned methods was excluded from the survey
database. Pneumococcal vaccination data for 2-year-olds during 2008–10, 2011–13, 2014–16
and 2017–19, were included in the study with cumulative survey response rates of 80.5%,
77.4%, 72% and 68.2%, respectively. For 8-year-olds, only pneumococcal vaccination data
during the last two survey periods, 2014–16 and 2017–19, were included with response
rates of 70.9% and 68.2%, respectively. Data from earlier survey periods were excluded as
PCV use was still not widespread for the respective age groups during those periods. Data
was anonymized prior to statistical processing.
2.2. Case Definition and Regional Assignment
An IPD case was defined as a patient from whom an invasive isolate was confirmed
by the NZPn. Information on the isolates used in this study were not linked to physician
cases. Hence, these counts do not represent the absolute numbers of IPD cases monitored
by the FOPH in Switzerland.
Western Switzerland was considered as primarily French and Italian speaking can-
tons, which includes cantons Fribourg, Geneva, Jura, Neuchatel, Vaud, Valais and Ticino
(Figure S1). The remaining 19 primarily German speaking cantons were considered eastern
Switzerland. Isolates with missing residence canton information (~16%) were assigned to
the canton region of the referring (local) laboratory, where possible.
2.3. Statistical Analyses
Annual IPD incidences during 2005–2019 were calculated overall and for age groups
(<5, 5–64 and ≥65 years), using the yearly number of IPD isolates as the numerator and
corresponding annual population estimates, obtained from the Swiss Federal Statistics Of-
fice (https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung.html, accessed
on 10 December 2020), as the denominator. Regional incidences were calculated based on
previously defined cantonal groupings. For overall analysis, incidence rate ratios (IRRs)
were estimated to allow pairwise comparisons between the early PCV7 (2005–2007), late
PCV7 (2008–2010), early PCV13 (2011–2013), mid PCV13 (2014–2016) and late PCV13 eras
(2017–2019). For regional analysis, IRRs between regions were compared using the east as
reference. Incidence and rate ratios were calculated using the poisson exact test (R package
epitools v0.5–10.1) and rate ratio function (R package fmsb v0.7.0) respectively.
Annual serotype distribution proportions were estimated for individual serotypes
and stratified by PCV-type (PCV7, PCV13nonPCV7 and non-PCV) and age groups. Trend
analyses were performed using the Chi-squared test for trend in proportions. Annual
serotype incidences were calculated overall and for regions by multiplying annual serotype
(individual or PCV-type) proportions by the annual incidence.
As previously described, vaccination survey data were first weighted to account for
sampling design and adjusted for non-response [16]. Vaccination coverage estimates and
95% confidence intervals (95% CI) for the Swiss population were then calculated for each
region per PCV era using the survey option in Stata (v13.1). Timeliness of vaccine uptake
was plotted using the cumulative proportion of administered doses by age. Regional
differences in vaccine coverage proportions were estimated with the two-proportion z-test.
For all analyses, p < 0.05 was considered significant. Excluding vaccination coverage
estimates, all other analyses were performed using R (v3.6.1) in the RStudio environment
(v1.2.1335).
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3. Results
3.1. Characteristics of IPD from 2005–2019
In total, 14680 laboratory-confirmed isolates of invasive pneumococcal disease were
reported in Switzerland during 2005–2019. Of these, the majority (92.6%) of S. pneumoniae
were isolated from blood, 2.1% from CSF and the remaining from other diverse body sites.
The absolute number of invasive isolates increased from 1016 in 2005 to 1129 in 2008 and
steadily decreased to 877 in 2016 (Table S1). Total invasive isolates then spiked up to 1012
in 2017 before falling to 915 in 2019. In total, 4.9% (n = 714) were collected from children
aged <5 years, 36.5% (n = 5355) from those aged 5–64 years and 52.5% (n = 7707) from
adults ≥65 years (Table S1). Overall, 904 (6.2%) isolates had missing data for age.
3.2. Overall Impact of PCV on IPD Incidence and Serotype Distribution in Switzerland
After the introduction of PCV7 in 2006, overall IPD incidence slightly decreased
from a peak of 14.1 cases in 2008 to 12.5 cases per 100.000 population in 2010. Following
PCV13′s implementation in 2011, IPD incidence further decreased to 10.4 cases per 100.000
population in 2016, followed by a temporary rebound in 2017, which was more pronounced
among adults aged ≥65 years (Figure 1A). In subsequent years, the rebound in total cases
declined (Figure 1A).
When comparing PCV eras, strong effects of PCV7 were observed during the late
PCV7 era (2008–2010), evidenced by the lower PCV7-type IPD incidence across all age
groups (Figure 1B; Table 1). This was more pronounced in children <5 years, where the
decline was 68% lower compared to the early PCV7 era (2005–2007) (Figure 1C; IRR 0.32,
95% CI 0.23–0.46).
After PCV13 introduction, incidence of PCV7-type IPD continued to decline and by
the late PCV13 era had decreased 85% across all ages compared to the early PCV7 era
(Table 1). However, overall IPD incidence was only 16% lower, as non-PCV-type IPD cases
continued to increase among age groups ≥ 5 years (Table 1; Figure 1C). No significant
decreases in total IPD incidence were observed for age groups, when comparing mid- and
late-PCV13 eras (Table 1).
Of individual vaccine serotypes (VTs), incidence of serotype 3 IPD did not decrease
after PCV13 introduction and remained predominantly high among adults ≥65 years
(Figure 2; Table S2). In addition, non-vaccine serotypes (NVTs) which increased post-
PCV13 introduction were most prevalent in adults ≥65 years (Table 1; Figure 2). Of these,
serotypes 8, 22F and 9N contributed the highest IPD incidence (Figure 2). By the end of
2019, NVTs were responsible for 70% of all IPD cases compared to 21% by PCV13nonPCV7
and 9% by PCV7 serotypes (Table S2).
































































































































Figure 1. Incidence of invasive pneumococcal disease in Switzerland during 2005–2019. Overall incidence stratified by (A)
age group, (B) vaccine serotype and (C) age group and vaccine serotype. Introduction of PCV7 (2006) and PCV13 (2011) are
indicated by dotted black lines.
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IRR b (95% CI)
Early PCV13 vs.
Late PCV7
IRR b (95% CI)
Mid PCV13 vs.
Early PCV13
IRR b (95% CI)
Late PCV13 vs.
Mid PCV13
IRR b (95% CI)
Late PCV13 vs.
Early PCV7
IRR b (95% CI)
<5 years n = 219 n = 188 n = 127 n = 91 n = 89
PCV7 11.1 (9.2–13.2) 3.6 (2.6–4.8) 1.5 (0.9–2.3) 0.6 (0.3–1.2) 0.5 (0.2–1.1) 0.32 (0.23–0.46) 0.42 (0.24–0.72) 0.42 (0.19–0.98) 0.85 (0.31–2.34) 0.05 (0.02–0.10)
PCV13nonPCV7 5.4 (4.1–6.9) 9.7 (8.0–11.6) 5.8 (4.5–7.3) 2.5 (1.7–3.6) 2.4 (1.7–3.5) 1.80 (1.31–2.47) 0.60 (0.44–0.80) 0.44 (0.29–0.66) 0.97 (0.60–1.59) 0.46 (0.30–0.70)
Non-PCV 3.5 (2.4–4.7) 3.1 (2.2–4.3) 3.2 (2.3–4.4) 4.0 (3.0–5.3) 3.8 (2.8–5.0) 0.91 (0.58–1.43) 1.02 (0.65–1.61) 1.25 (0.82–1.90) 0.95 (0.65–1.41) 1.11 (0.73–1.69)
Total cases 19.9 (17.4–22.7) 16.4 (14.1–18.9) 10.5 (8.7–12.4) 7.2 (5.8–8.8) 6.8 (5.5–8.4) 0.82 (0.68–1.0) 0.64 (0.51–0.80) 0.68 (0.52–0.90) 0.95 (0.71–1.27) 0.34 (0.27–0.44)
5–64 years n = 1129 n = 1308 n = 1103 n = 879 n = 936
PCV7 2.6 (2.4–2.9) 2.2 (2.0–2.5) 0.9 (0.8–1.0) 0.4 (0.3–0.5) 0.5 (0.4–0.6) 0.84 (0.74–0.96) 0.40 (0.34–0.48) 0.47 (0.36–0.61) 1.23 (0.91–1.65) 0.19 (0.16–0.24)
PCV13nonPCV7 2.2 (2.0–2.5) 2.9 (2.7–3.2) 2.8 (2.5–3.0) 1.5 (1.3–1.6) 1.1 (0.9–1.2) 1.31 (1.15–1.49) 0.94 (0.84–1.06) 0.53 (0.46–0.61) 0.73 (0.61–0.88) 0.48 (0.41–0.57)
Non-PCV 1.5 (1.3–1.6) 2.0 (1.8–2.2) 2.2 (2.0–2.5) 2.7 (2.5–2.9) 3.2 (2.9–3.5) 1.36 (1.16–1.60) 1.12 (0.97–1.29) 1.2 (1.06–1.37) 1.19 (1.06–1.33) 2.18 (1.89–2.52)
Total cases 6.3 (6.0–6.7) 7.2 (6.8–7.6) 5.9 (5.5–6.2) 4.6 (4.3–4.9) 4.8 (4.5–5.1) 1.13 (1.04–1.22) 0.82 (0.76–0.89) 0.78 (0.71–0.85) 1.05 (0.95–1.15) 0.75 (0.69–0.82)
≥65 years n = 1471 n = 1617 n = 1518 n = 1467 n = 1634
PCV7 19.7 (18.3–21.2) 14.3 (13.1–15.5) 7.0 (6.3–7.9) 3.8 (3.3–4.5) 2.6 (2.2–3.1) 0.72 (0.65–0.81) 0.50 (0.43–0.57) 0.55 (0.45–0.66) 0.68 (0.54–0.85) 0.13 (0.11–0.16)
PCV13nonPCV7 11.8 (10.7–13) 14.8 (13.6–16.1) 14.6 (13.5–15.8) 9.6 (8.7–10.5) 8.2 (7.4–9.0) 1.25 (1.11–1.42) 0.98 (0.88–1.10) 0.66 (0.58–0.74) 0.85 (0.74–0.98) 0.69 (0.60–0.79)
Non-PCV 8.7 (7.8–9.7) 12.1 (11.0–13.2) 14.6 (13.4–15.8) 19.3 (18.0–20.6) 23.8 (22.4–25.2) 1.39 (1.21–1.60) 1.20 (1.07–1.36) 1.32 (1.2–1.47) 1.23 (1.13–1.34) 2.73 (2.41–3.09)
Total cases 40.3 (38.2–42.4) 41.2 (39.2–43.2) 36.2 (34.4–38.0) 32.7 (31.1–34.4) 34.5 (32.9–36.2) 1.02 (0.95–1.10) 0.88 (0.82–0.94) 0.90 (0.84–0.97) 1.06 (0.98–1.13) 0.86 (0.80–0.92)
All ages n = 3031 n = 3237 n = 2929 n = 2612 n = 2871
PCV7 6.2 (5.9–6.5) 4.5 (4.2–4.7) 2.1 (1.9–2.3) 1.1 (1.0–1.3) 0.9 (0.8–1.1) 0.72 (0.66–0.78) 0.47 (0.42–0.52) 0.53 (0.46–0.62) 0.83 (0.70–0.99) 0.15 (0.13–0.17)
PCV13nonPCV7 4.3 (4.0–4.6) 5.5 (5.2–5.8) 5.3 (5.0–5.6) 3.2 (2.9–3.4) 2.7 (2.5–2.9) 1.28 (1.18–1.39) 0.96 (0.88–1.04) 0.6 (0.55–0.66) 0.85 (0.76–0.94) 0.62 (0.56–0.69)
Non-PCV 2.9 (2.7–3.2) 3.9 (3.7–4.2) 4.8 (4.5–5.1) 6.2 (5.9–6.5) 7.6 (7.3–8.0) 1.33 (1.21–1.47) 1.22 (1.12–1.33) 1.3 (1.2–1.4) 1.23 (1.15–1.31) 2.59 (2.37–2.83)
Total cases 13.4 (13.0–13.9) 13.9 (13.4–14.3) 12.1 (11.7–12.6) 10.5 (10.1–10.9) 11.2 (10.8–11.6) 1.03 (0.98–1.08) 0.88 (0.83–0.92) 0.86 (0.82–0.91) 1.07 (1.02–1.13) 0.83 (0.79–0.88)
a Incidence per 100′000 population (95% CI). b IRR = Incidence rate ratio. Significant changes in rate ratios in bold. c Includes cases of unknown age categories (Total unknown = 904).

































































































Figure 2. Single Serotype analyses in Switzerland, 2005–2019. Single serotypes with high IPD
incidences are indicated. Certain serotypes have not been part of the routine typing in Switzerland
for 2005–2006 (hence the data is shaded). Introduction of PCV7 (2006) and PCV13 (2011) are indicated
by dotted black lines.
3.3. Overall Impact of PCV on IPD Incidence in Eastern and Western Switzerland
The majority of IPD isolates were reported in the eastern (n = 10600; 72.2%) as com-
pared to the western region (n = 4067; 27.7%) and unknown origin (n = 13; 0.09%). Within
the two Swiss regions, IPD incidence again showed a declining trend during 2005–2019,
which was mostly lower in the west compared to the east, except for the early PCV7 and
early PCV13 eras (Table 2; Figure 3A). After the early PCV13 era, incidence of VT-type IPD
continued to decrease in both regions, though more significantly in the west than the east,
whereas non-PCV-type IPD showed a higher significant increase in the east than the west
during the late PCV13 era (Table 2; Figure 3B).
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Table 2. Incidence of invasive pneumococcal disease cases (isolates) by region and PCV serotypes, Switzerland 2005–2019.





2005–2007 (early PCV7 era)
PCV7 993 408 6.2 6.1 0.98 0.88–1.11
PCV13nonPCV7 673 292 4.2 4.4 1.04 0.91–1.19
Non-PCV 456 206 2.9 3.1 1.08 0.92–1.28
Total cases 2122 906 13.3 13.6 1.02 0.95–1.10
2008–2010 (late PCV7 era)
PCV7 814 225 5.0 3.2 0.65 0.57–0.76
PCV13nonPCV7 924 355 5.6 5.1 0.91 0.81–1.03
Non-PCV 634 284 3.9 4.1 1.06 0.92–1.22
Total cases 2372 864 14.4 12.5 0.86 0.80–0.93
2011–2013 (early PCV13 era)
PCV7 365 139 2.2 1.9 0.89 0.74–1.09
PCV13nonPCV7 895 376 5.3 5.2 0.99 0.88–1.11
Non-PCV 780 374 4.6 5.2 1.13 1.00–1.27
Total cases 2040 889 12.1 12.3 1.02 0.95–1.11
2014–2016 (mid-PCV13 era)
PCV7 226 52 1.3 0.7 0.54 0.40–0.72
PCV13nonPCV7 585 203 3.3 2.7 0.81 0.69–0.95
Non-PCV 1110 436 6.4 5.8 0.91 0.82–1.02
Total cases 1921 691 11 9.2 0.84 0.77–0.91
2017–2019 (late PCV13 era)
PCV7 193 44 1.1 0.6 0.53 0.38–0.74
PCV13nonPCV7 523 159 2.9 2.1 0.71 0.59–0.85
Non-PCV 1429 514 8.0 6.7 0.84 0.76–0.93
Total cases 2145 717 12 9.3 0.78 0.72–0.85
West region was defined as primarily French & Italian speaking cantons: Jura (JU), Geneva (GE), Fribourg (FR), Neuchâtel (NE), Valais
(VS), Vaud (VD) & Ticino (TI). All other cantons were defined as East. IRR = Incidence rate ratio. Significant changes in IRR are in bold.
Serotypes included in PCV7: 4, 6B, 9V, 14, 18C, 19F & 23F. Additional serotypes included in PCV13, but not PCV7: 1, 3, 5, 6A, 7F & 19A.






















































Figure 3. Incidence of invasive pneumococcal disease by region in Switzerland, 2005–2019. Regional incidence is illustrated
(A) overall and (B) stratified by vaccine serotype. 95% confidence intervals are depicted as the shaded region between
ribbon dashed lines. Introduction of PCV7 (2006) and PCV13 (2011) are indicated by dotted black lines.
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3.4. Pneumococcal Vaccine Coverage in National and Regional Switzerland
Among children aged 2 years-old (target population), who were vaccinated with at
least one PCV dose, uptake rates increased from 53% (95% CI, 49.6–56.4%) during the
late PCV7 era to 88% (86.8–88.9%) during the late PCV13 era (Figure 4A). Similar upward
trends in the timeliness of PCV uptake were noted for second and third doses (Figure 4A).
When stratified by region, pneumococcal vaccine coverage rates increased in the east from
43%, 40% and 26% during the late PCV7 era to 87%, 86% and 83% during the late PCV13
era for doses one, two and three in the target population, respectively (Figure 4B; Figure
S2A,B). In the west, coverage rates were significantly higher (p < 0.001) and increased
from 71%, 67% and 57% during the late PCV7 era to 91%, 90% and 80% during the late
PCV13 era for doses one, two and three in the target population, respectively (Figure 4B;
Figure S2A,B). Among 8-year-old children selected for the vaccine uptake surveys, similar
regional differences were also observed during the last two PCV eras (Figure S3A–D).
3.5. Indirect and Overall Impact of PCV Coverage on IPD Incidence in Age Group Populations in
the East and West
We next stratified our IPD incidence data according to the east/west region and
respective age groups. We hypothesized that increased PCV coverage may be associated
with decreased IPD incidence, either through a ‘direct effect’ (in the children <5 years) or
an ‘indirect effect’ (mainly for adults ≥65 years).
For the early PCV7 era (2005–2007), our hypothesis was unsupported, as we observed
lower IPD incidences among age group extremes (children <5 years and adults ≥65 years),
despite extremely low vaccine coverage rates of this era (Figure 4B; Supplementary Tables
S3–S5). However, given that such regional differences were not observed for overall
IPD incidence, caution should be taken when interpreting this age group-stratified result,
especially since a higher proportion of unknown age group cases were observed in the
west compared to the east during this period.
In the late PCV7 era (2008–2010), support for our hypothesis was corroborated by
higher PCV7 uptake rates in the west and a significant decrease in the IPD incidence of
adults ≥65 years in this region, possibly as an indirect effect of the higher vaccine coverage
in the west (Figure 4B; Table S5). In the ensuing (PCV13) era (2011–2013), IPD incidence
remained lower in the west, albeit not significantly, as incidence proportions sharply
decreased in the east, especially among adults ≥65 years, probably due to a 92.5% increase
in PCV coverage (2 doses) in the east, which minimized coverage differences between both
regions and the incidence gap between aged adults in these regions (Figure 4B).
However, during the mid- and late- PCV13 eras, increasing incidence of non-PCV-type
IPD was observed in both regions, where they rose 78% among adults ≥65 years living in
the east, compared to 30% among those in the west, widening the incidence gap between
both regions (Figure 4B,C; Table S5).
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Figure 4. Timeliness of pneumococcal conjugate vaccine uptake, regional estimates of coverage and age-group specific
incidence in Switzerland, 2005–2019.(A) Timeliness of vaccine uptake in children aged 2-years, vaccinated with 1–3 doses of
PCV7 or PCV13, (B) age group-specific IPD incidence and regional estimates of pneumococcal vaccination coverage among
children aged 2-years with 1–2 PCV doses, and (C) age group- and region-stratified IPD incidence by vaccine serotypes.
95% confidence intervals are depicted by (A) shaded regions and (B) error bars. For the combined graph (B), the primary
Y-axis shows the IPD cases per 100′000 population (line graph) and the secondary Y-axis shows the vaccine uptake rates (bar
graph). Introduction of PCV7 (2006) and PCV13 (2011) are indicated by dotted black lines (C). Proportions and vaccination
coverage estimate during the 2005–2007 period were excluded due to very low rates (<3%). *** indicates p < 0.001 (Two
proportions z-test).
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4. Discussion
In this population-based study, we examined the overall impact of PCV7 and PCV13
introduction on IPD in Switzerland as well as the influence of PCV coverage heterogeneities
in the country’s largely German (east)- and French/Italian (west)- speaking regions during
2005–2019.
Unsurprisingly, we observed large reductions in VT-type IPD across all age groups
after the introduction of both PCV7 and PCV13 in the country, with an earlier and pro-
nounced effect in children <5 years, which has been reported in other studies [17,18]. In
contrast, the indirect beneficial effects among age groups, 5–64 years and adults ≥65 years
were countered by increasing incidence of non-PCV-type IPD during the late PCV13 era,
resulting in an overall IPD incidence that was only 24% and 14% lower, for the respective
age groups, compared to the early PCV7 era. Interestingly, the rise in non-PCV-type IPD
actually resulted in a rebound of total IPD cases in 2017. This rebound in cases has also
been observed in studies from other European countries [18,19]. In England and Wales [18],
high influenza activity was reported during the rebound years, which in lieu of an absence
of indirect PCV effects, may partly explain the temporary increase in IPD cases. This may
also be the case for our Swiss study, though we have yet to analyze the influenza data
in detail.
The rising incidence of non-PCV-type IPD after PCV13 introduction, solely among
older age groups, especially adults ≥65 years, is concerning. Though these findings are
largely consistent with England and Wales [18], studies in the USA have not demonstrated
similar trends in their adult population [20]. Lewnard et al. attempted to make sense
of these discrepancies and suggested a number of explanations including differences in
surveillance sampling, exposure sources and lineage evolution [21]. Of these, we mostly
concur that the alarming rise in IPD incidence of some NVTs (8, 22F & 9N) in the aged
population, may stem from changes in the usual exposure source (children <5 years), given
that these serotypes have been found to be either absent in carriage [22], or carried at a low
prevalence (<5%) [23–25], suggesting the possibility of other age groups being potential
reservoirs or exposure sources for their transmission.
On the national level, our results demonstrated an unclear impact of PCV13 on
serotype 3 IPD due to relatively few episodes in children <5 years, and high—albeit
fluctuating—incidence among adults ≥65 years. These findings are also consistent with
large surveillance studies in France, England and Wales and may hint at a lack of an indirect
protection against this serotype in the older age group [18,19]. In Sweden and Portugal,
the increased prevalence of serotype 3 in adults ≥65 years was tied to an expansion of a
clonal complex, CC180 [26,27], which—as another study showed—had produced a new
genetic lineage in the post-PCV13 era with higher antibiotic resistance, recombination
rate and antigenic variation than the pre-PCV13 lineages [28]. Antigenic variation may
explain the persisting incidence of serotype 3 in adults ≥65 years, but it doesn’t explain
its exclusivity to this age group. As for the younger age groups, a recent study recruited
children with blood culture-proven sepsis due to Streptococcus pneumoniae and it was
observed that the incidence of pneumococcal sepsis shortly after introduction of PCV-13
remained substantial [29]. In addition, it was shown that disease caused by serotype
3 represented significant predictors of severity [29]. Further studies are therefore necessary
to better understand the immunological response induced by PCV13 against the serotype
3 polysaccharide.
In Switzerland, PCVs are generally well accepted by the population and uptake has
reached >80% in more recent years. Based on our data, vaccine uptake is higher in the
West (mainly French speaking cantons) compared to the East (German speaking cantons).
Recently, a descriptive study based on administrative claims data from a single Swiss
health insurer (Helsana) was performed in cohorts of children born between January 2010
and December 2016 [30]. The authors found similar regional differences as outlined in
this study and concluded that more emphasis should be placed on timely vaccination [30].
Another recent study in Switzerland demonstrated that teenage girls living in a French-
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speaking municipality were two times more likely to be vaccinated against HPV compared
to those living in the German/Italian-speaking regions [13]. However, after adjusting for
other covariates (full model), the authors found that language region was highly corre-
lated with school-based vaccinations and a popular voting result about vaccination laws
(vaccine skepticism). We hypothesize that vaccine skepticism may also play a role in the
observed regional differences in PCV uptake, however, this warrants further investigation
in another study.
Our data shows a correlation of decreased IPD incidence with higher vaccine uptake
in the west. However, correlation does not mean causation as factors other than vaccine
uptake are also plausible for the observed regional differences in IPD incidences. Among
these, clinical practices for investigation and treatment of patients with suspected IPD, as
well as case ascertainment and surveillance differences should be considered. Nevertheless,
while these variables should be considered if IPD data are compared between nations [18],
we believe that given the national guidelines in place, the regional differences for the above
explanations will probably have a minimal effect.
Our study has a number of limitations. First, the reported annual incidence of IPD
cases among children <5 years, though similar to Sweden [17], is relatively low compared
to other countries [18–20], which may indicate an under-reporting for mild IPD cases and
an underestimation of IPD incidence within this age group in Switzerland [31]. Second, our
surveillance dataset had a significant number of IPD cases with unknown ages presenting
from the west during 2005–2013 and we could not correct for this confounding. Although
this does not affect overall results in both regions, our observation on the indirect herd
effects among age group populations during this period in the west should be interpreted
with caution. Third, surveillance records did not include information on vaccination
history, comorbidities or IPD-related deaths of patients, preventing an in-depth evaluation
of serotype-specific association with regions. Lastly, we did not include additional pre-
vaccine (2001–2004) data, which may have provided insights on natural fluctuations and
temporal trends of circulating pneumococcal strains. However, data from this period has
already been examined [32] and we maintain that overall interpretations would remain the
same, as we primarily focused on matching periods of vaccine uptake and IPD surveillance.
The strength of our study lies in the use of two highly representative nationwide
datasets from the Swiss national vaccination coverage survey and invasive pneumococcal
disease surveillance, spanning 15 years of PCV implementation and allowing for a longer
post-vaccine follow-up. Also, our IPD surveillance record of serotypes represents a highly
uniform methodology via a national reference laboratory with high participation from
local laboratories.
5. Conclusions
We report an overall decreased IPD incidence across all age groups in Switzerland,
with pronounced reductions in children <5 years following the introduction of both PCV7
and PCV13 in the country during 2005–2019. We also observed a predominance of lower
IPD incidences in the west associated with higher vaccination coverage compared to the
east, though coverage continues to show an overall increasing trend in both regions with
decreased IPD incidence. The increasing incidence of non-PCV-type IPD in adults ≥65
years, especially serotypes 8, 22F and 9N, as well as the persistence of serotype 3 in this
age group may hint at a need for an exclusive conjugate vaccine for serotypes affecting
this group. Continued surveillance therefore remains a priority for early detection of
serotype replacement and future vaccine development. At the same time, efforts to further
improve vaccination coverage, which at present is >80%, may help further decrease IPD
transmission in Switzerland.
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